Retatrutide vs Tirzepatide vs Semaglutide: The Complete Head-to-Head Comparison

The GLP Peptide Hierarchy: Three Generations of Incretin Research

Three generations of GLP peptides. Three different receptor profiles. Vastly different weight loss outcomes in head-to-head clinical data. This is the complete comparison researchers need before deciding which compound to study.

The Core Comparison Table

Feature

Semaglutide (GLP-1 S)

Tirzepatide (GLP-2 T)

Retatrutide (GLP-3 R)

Receptors	GLP-1 only	GLP-1 + GIP	GLP-1 + GIP + Glucagon
Max weight loss	−17.4%	−22.5%	−28.7%
Trial	STEP 1 (68 wk)	SURMOUNT-1 (72 wk)	TRIUMPH-4 (68 wk)
Participants	1,961	2,539	5,800+
≥5% loss	86.4%	91%	100%
≥20% loss	32%	57%	71%
Thermogenesis	No	Minimal	Yes (BAT activation)
Liver fat reduction	~30%	~50%	~82%

Mechanism Breakdown

Semaglutide — Single Receptor (GLP-1)

Semaglutide (CAS: 910463-68-2) is a 31-amino acid GLP-1 analog with C18 fatty diacid lipidation that extends half-life to ~7 days. It activates only the GLP-1 receptor, which:

• Stimulates POMC/CART neurons in the arcuate nucleus → appetite suppression
• Inhibits NPY/AgRP neurons → reduced hunger signaling
• Delays gastric emptying → increased satiety
• Stimulates glucose-dependent insulin secretion

The STEP 1 trial (2021, NEJM) with 1,961 participants showed −14.9% at 68 weeks in the 2.4mg/week arm, with 86.4% achieving ≥5% loss.

Limitations: Single-pathway mechanism. No effect on metabolic rate. No thermogenesis. Insulin resistance in adipose tissue not addressed.

Tirzepatide — Dual Receptor (GLP-1 + GIP)

Tirzepatide (CAS: 2023788-19-2) adds GIP receptor agonism to GLP-1, creating a genuinely additive effect:

• GIP receptor in adipose tissue: Improves insulin sensitivity directly in fat cells → enhanced lipolysis when insulin-sensitive adipocytes properly respond to insulin-driven fat mobilization
• GIP in pancreas: Potentiates glucose-stimulated insulin secretion beyond GLP-1 alone
• Combined satiety: Dual receptor activation produces stronger satiety signaling than either alone

The SURMOUNT-1 trial (2022, NEJM) with 2,539 participants showed −22.5% at 72 weeks in the 15mg arm, with 91% achieving ≥5% and 57% achieving ≥20%.

Compared to semaglutide, this represents approximately +5-8% additional weight loss — attributable to the GIP receptor's adipose-tissue effects.

Retatrutide — Triple Receptor (GLP-1 + GIP + Glucagon)

Retatrutide (CAS: 2381609-35-2) adds glucagon receptor activation to tirzepatide's dual mechanism. This third receptor is the critical differentiator:

Glucagon receptor effects:

• Stimulates hepatic gluconeogenesis (increases glucose output from liver)
• Induces lipolysis in adipose tissue independent of insulin
• Activates brown adipose tissue (BAT) thermogenesis → increases resting energy expenditure
• Promotes production of non-esterified fatty acids and ketone bodies
• Enhances hepatic fat oxidation → −82.4% liver fat in Phase 2

The thermogenesis effect is unique to Retatrutide. While semaglutide and tirzepatide only reduce caloric intake, Retatrutide simultaneously increases how many calories the body burns at rest — a two-sided attack on energy balance.

TRIUMPH-4 Phase 3 (2025, 5,800+ participants) showed −28.7% at 68 weeks in the 12mg arm:

• 100% of participants achieved ≥5% loss
• 71% achieved ≥20% loss
• Average absolute loss: 71.2 lbs

The Liver Fat Data: Retatrutide's Biggest Differentiator

The most striking comparison isn't weight loss — it's liver fat:

Peptide

Liver Fat Reduction

Semaglutide	~30%
Tirzepatide	~50%
Retatrutide	−82.4% (Phase 2, 12mg)	Retatrutide's glucagon receptor activation drives hepatic fat oxidation at a scale neither competitor approaches. For NAFLD/NASH research, this is the critical data point. Side Effect Comparison	Side Effect	Semaglutide	Tirzepatide	Retatrutide

Nausea	44%	31%	43%
Diarrhea	30%	22%	34%
Vomiting	24%	13%	24%
Discontinuation	7%	9%	18.2%

Retatrutide has a higher discontinuation rate — consistent with its stronger pharmacological activity at the glucagon receptor producing more significant GI effects at higher doses.

Which Compound for Which Research?

Use semaglutide (GLP-1 S) for:

• Established GLP-1 mechanism studies with the most published reference data
• Budget-constrained protocols (lowest cost per mg)
• Cardiovascular outcome research (SUSTAIN-6 CV data)

Use tirzepatide (GLP-2 T) for:

• Dual incretin mechanism studies
• Comparing GIP contribution to GLP-1 effects
• Best safety/efficacy ratio with strong Phase 3 data

Use retatrutide (GLP-3 R) for:

• Maximum weight loss models
• Thermogenesis and energy expenditure research
• Liver fat / NAFLD research
• Triple vs dual vs single agonism comparison protocols

Conclusion

Each generation adds a receptor and meaningfully improves outcomes. The data is unambiguous: triple agonism (Retatrutide) produces the greatest weight reduction, liver fat reduction, and — uniquely — thermogenic energy expenditure increases. For researchers studying the outer limits of GLP-mediated weight loss biology, Retatrutide is the only compound that achieves all three simultaneously.

All compounds available from Clav Tides. Research-grade, >98% HPLC purity, free shipping over $200.